Investigational drug · Phase 3
XTR004
Also called: 99mTechnicium Sestamibi, Procedure: Coronary angiography
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronary Artery Disease(CAD).
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "XTR004"
First trial start
2025
Nov 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XTR004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Coronary Artery Disease(CAD)
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "XTR004" as an intervention, largest first.
- Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)Pivotal-lookingRecruiting
Sinotau Pharmaceutical GroupIndustry
NCT07439133 · 395 participants (planned) · Start Nov 14, 2025 · Primary completion Jun 2027
Drug: XTR004 · For: Coronary Artery Disease(CAD)
Sites: Beijing, China; Foshan, China; Tianjin, China · 5 sites in all
Peking Union Medical College HospitalAcademic, hospital or other
NCT04596527 · 100 participants (planned) · Start Sep 15, 2020 · Primary completion Jun 2022
Drug: 18F-FMPP · For: Coronary Disease
Sites: Beijing, China
- Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CADCompleted
Sinotau Pharmaceutical GroupIndustry
NCT05885841 · 83 participants · Start Feb 15, 2022 · Primary completion May 9, 2023
Drug: XTR004 · For: Coronary Artery Disease (CAD)
Sites: Beijing, China · 2 sites in all
Sinotau Pharmaceutical GroupIndustry
NCT07187895 · 17 participants · Start Dec 19, 2024 · Primary completion Mar 5, 2025
Drug: XTR004 · For: Myocardial Perfusion Imaging; Diagnostic Certainty; Stable Coronary Artery Disease
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Comparative evaluation of a novel [18F] F-Labeled PET tracer XTR004 against [13N] ammonia in myocardial perfusion imaging for coronary artery disease.
Wang P, Ren C, Wang L, et al. · Eur J Nucl Med Mol Imaging 2025
- Comparison of Small Blood Vessel Diameter with Intravascular Ultrasound and Coronary Angiography for Guidance of Percutaneous Coronary Intervention.
Zuñiga-Mendoza SA, Zayas-Diaz E, Armenta-Velazquez VR, et al. · Diagnostics (Basel) 2024
- Phase I, first-in-human study of XTR004, a novel 18F-labeled tracer for myocardial perfusion PET: Biodistribution, radiation dosimetry, pharmacokinetics, and safety after a single injection at rest.
Ren C, Pan Q, Fu C, et al. · J Nucl Cardiol 2024
- [Monocentric experience of the RenalGuard® system to limit post-contrast acute kidney injury in patients at high-risk undergoing interventional coronary procedures].
Elleuch A, Hebbo A, Steinecker M, et al. · Ann Cardiol Angeiol (Paris) 2022
- Sudden death after valve-in-valve procedure due to delayed coronary obstruction: a case report.
Buscaglia A, Tini G, Bezante GP, et al. · J Med Case Rep 2018
- The T29C (rs1800470) polymorphism of the transforming growth factor-β1 (TGF-β1) gene is associated with restenosis after coronary stenting in Mexican patients.
Fragoso JM, Zuñiga-Ramos J, Arellano-González M, et al. · Exp Mol Pathol 2015
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.